We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+12.24%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
-$171M
Cap. Flow
-$111M
Cap. Flow %
-7.89%
Top 10 Hldgs %
67.5%
Holding
33
New
7
Increased
5
Reduced
12
Closed
3

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$71M
2
INSM icon
Insmed
INSM
+$47.7M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$34.8M
4
OMER icon
Omeros
OMER
+$16.7M
5
EPZM
Epizyme, Inc
EPZM
+$16.5M

Top Sells

Rank Stock Value
1
MYGN icon
Myriad Genetics
MYGN
+$110M
2
AMRN
Amarin Corp
AMRN
+$43.5M
3
UTHR icon
United Therapeutics
UTHR
+$42.5M
4
PCRX icon
Pacira BioSciences
PCRX
+$36.2M
5
VCEL icon
Vericel Corp
VCEL
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
26
Krystal Biotech
KRYS
$10.3B
$7.33M 0.52%
+182,090
New +$5.95M
SVRA icon
27
Savara
SVRA
$1.13B
$3.72M 0.26%
1,568,002
-1,525,688
-49% -$13.6M
IMMU
28
DELISTED
Immunomedics Inc
IMMU
$2.01M 0.14%
145,000
– –
ARQL
29
DELISTED
Arqule Inc
ARQL
$551K 0.04%
+50,000
New +$348K
QTTB icon
30
Q32 Bio
QTTB
$463M
$512K 0.04%
+1,453
New +$571K
AKBA icon
31
Akebia Therapeutics
AKBA
$354M
– –
-1,430,579
Closed -$11.7M
MYGN icon
32
Myriad Genetics
MYGN
$295M
– –
-3,309,206
Closed -$110M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Consonance Capital Management held 33 positions worth $1.41B, down 11% from $1.58B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Consonance Capital Management withdrew a net $111M in Q2 2019, closing 3 positions and reducing 12 holdings. Its most notable exit was Myriad Genetics, an estimated $110M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Insmed worth $43.8M.

  • Consonance Capital Management's largest Q2 2019 buy was Insmed: 1,711,150 shares worth $43.8M.
  • Consonance Capital Management added most to Iovance Biotherapeutics in Q2 2019, an estimated $71M increase.
  • Consonance Capital Management's biggest Q2 2019 reduction was Amarin Corp, cutting an estimated $43.5M.
  • Consonance Capital Management fully exited Myriad Genetics in Q2 2019, selling an estimated $110M.
  • Consonance Capital Management's ten largest holdings make up 67% of its $1.41B portfolio in Q2 2019.
  • Consonance Capital Management opened 7 new positions and closed 3 in Q2 2019.
  • Consonance Capital Management's portfolio value fell 11% quarter-over-quarter to $1.41B.

Based on Consonance Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.